A decade of hypocretin/orexin: Accomplishments in sleep medicine

Sleep Medicine Reviews

Volumn 13, Issue 1, 2009, Pages 5-8

  Thannickal, Thomas Chacko ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; ACETYLCHOLINESTERASE; ADENOSINE A1 RECEPTOR; AMPA RECEPTOR; DYNORPHIN; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; HLA DQB1 ANTIGEN; LEPTIN RECEPTOR; NEUROGLOBIN; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; PENTRAXIN; RECEPTOR SUBTYPE; SECRETOGRANIN II; SEROTONIN 1A RECEPTOR; STAT3 PROTEIN;

BEHAVIOR; BRAIN; CATAPLEXY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID LEVEL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG RESEARCH; EDITORIAL; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPOTHALAMUS; MEDICAL RESEARCH; NARCOLEPSY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PARASOMNIA; RECEPTOR GENE; SLEEP; SLEEP DISORDER;

ANIMALS; CATAPLEXY; HUMANS; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES;

EID: 58249091391     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smrv.2008.09.004     Document Type: Editorial

References (22)

1. Siegel J.M. Narcolepsy: a key role for hypocretins (orexins). Cell 98 (1999) 409-412
2. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95 (1998) 322-327
3. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
4. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
5. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
6. Nishino S., Ripley B., Overeem S., Lammers G.J., and Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 (2000) 39-40
7. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000) 991-997
8. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
9. Fronczek R., Bauman C.R., Lammers G.J., Bassetti C.L., and Overeem S. Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev 13 (2009) 9-22
10. Shchenko D., Murillo-Rodriguez E., Lin L., Xu M., Hallett L., Nishino S., et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 184 (2003) 1010-1016
11. Bourgin P., Zeitzer J.M., and Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 7 (2008) 649-662
12. Peyron C. Molecular characterization of hypocretin/orexin and melanin concentrating hormone neurons: relevance to narcolepsy. In: Bassetti C.L., Billiard M., and Mignot E. (Eds). Narcolepsy and hypersomnia (2006), Marcel Dekker Inc, New York 211-218
13. John J., Wu M.F., and Siegel J.M. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 3 (2000) 23-28
14. Siegel J.M. Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 55 (2004) 125-148
15. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., and Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 10 (2004) 4649-4654
16. Deadwyler S.A., Porrino L., Siegel J.M., and Hampson R.E. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 27 (2007) 14239-14247
17. Baier P.C., Weinhold S.L., Huth V., Gottwald B., Ferstl R., and Hinze-Selch D. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal orexin A (hypocretin-1). Brain (2008 Aug 21) [Epub ahead of print]
18. Brisbare-Roch C., Dingemanse J., Koberstein R., Hoever P., Aissaoui H., Flores S., et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13 (2007) 150-155
19. Thannickal T.C., Lai Y.Y., and Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130 (2007) 1586-1595
20. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130 (2007) 1577-1585
21. Saper C.B., Scammell T.E., and Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 437 (2005) 1257-1263
22. Thannickal T.C. Human narcolepsy as a neurodegenerative puzzle. Science 298 (2002) 767. http://www.sciencemag.org/feature/data/prizes/eppendorf/2002/thannickal.shtml